Jan 04, 2016
An agreement between two companies to invest in R&D, production and commercialisation of new products, is flourishing nearly 3 years after their initial meeting.
First brought together by Enterprise Europe Network team at RTC north in 2013, ImmonoSYS based in Manchester has been working with Dutch company Abunduz to produce and commercialise technology in therapeutic protein development.
Now, nearly 3 years after their initial meeting, the companies are considering merging and creating a new company based in the UK.
ImmunoSYS provides solutions to biological businesses through academia-to-industry translation of bioscience, with particular focus on immunology, proteins, probiotics and biomarkers.
Abundnz specialise in the development of innovative approaches and technologies in the biotechnology and diagnostics industries.
Masih Alam, ImmunoSYS, Director of Business Development said, “The cooperation has been fostered by EEN which is definitely a very effective platform.”
After the initial meeting facilitated by Leo Donato, RTC North, the companies composed a memorandum of understanding detailing a cooperation strategy based on:
Enterprise Europe Network
Getting a foothold in new markets can be a challenge. Enterprise Europe Network can help. Your local gateway to the European marketplace, it is Europe’s largest network for small companies with a presence in 53 countries. Funded by the European Commission and Innovate UK advisors work with businesses, universities and research bodies to help them make the most of opportunities overseas..
Enterprise Europe Network helps organisations interested in..